Catheter ablation has become a standard treatment strategy for drug-resistant symptomatic non-valvular atrial fibrillation (NVAF).
Catheter-based pulmonary vein (PV) ablation has emerged as an accepted therapy in patients with drug-resistant, symptomatic, paroxysmal, and persistent atrial fibrillation (AF).
Study Objective: Vaginal discharge in children is a common gynecologic complaint and may be resistant to symptomatic and/or antibiotic treatment.
Grades 3 4 non-haematological toxicity resistant to symptomatic treatment required epirubicin dose reduction to 60 mg/m.
There was a pressing clinical need for palliative therapy in patients who were not candidates for fractionated radiation therapy due to logistical issues and who had developed lesions that were chemotherapy-resistant and symptomatic.
Refractory chronic migraine (rCM [1] is a debilitating neurological disorder, characterized by headache on ≥ 15 days per month for > 3 months, resistant to conventional symptomatic and/or prophylactic polytherapy.
223Ra dichloride is an alpha-emitting radiopharmaceutical approved for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease.
Of note, a very recent randomized clinical study performed in subjects with drug-resistant HTN and symptomatic AF demonstrated significantly higher success rates of pulmonary vein ablation after 12 months if the procedure was combined with renal artery denervation [ 12].
47 48 Treatment of symptomatic UTI and UTI resistant to first line antibiotics was assumed to be managed in the community, whereas patients with multidrug resistant UTI, bacteraemia, or urethral complications were assumed to be treated in hospital.
The aqueous 223RaCl2 solution is licensed by the European Medicines Agency for treatment of adults with castration resistant prostate carcinoma with symptomatic bone metastasis without known visceral metastasis, and in May 2013 it was approved by the U.S. FDA for the treatment of bone metastases from prostate cancer as the first α-emitting radiopharmaceutical for clinical use (Kluetz et al., 2014).
In a trial of symptomatic hormone resistant prostate cancer [ 11, 12], 161 patients were randomized between prednisone alone (S) and prednisone plus mitoxantrone (T).
